Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug

A Phase I, Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Angiocal® (PRS-050-PEG40) in Patients With Solid Tumors

The purpose of this study is to determine if Angiocal® (PRS-050-PEG40) is safe and well tolerated when it is injected into the veins of patients with solid tumors. Other purposes of this study are to investigate how the body of the patients reacts to Angiocal®, how the blood level of Angiocal® develops after injection and how the tumor responds to the injection of Angiocal®.

Study Overview

• Status: Completed
• Conditions: Solid Tumor
• Intervention / Treatment: Drug: Angiocal® (PRS-050-PEG40)

Detailed Description

This is a phase I, open-label, dose escalation study with Angiocal® in patients with solid tumors using a group sequential adaptive treatment assignment. Patients will be allocated to different dose levels in small cohorts and will receive one single dose application on Day 1, followed by a repeated dosing period. The primary objective of the study is to evaluate the safety and tolerability of Angiocal® when administered intravenously to patients with solid tumors. The secondary objectives of the study are the characterization of the pharmacodynamic response, evaluation of the pharmacokinetic profile of Angiocal®, observation of tumor response.

• Study Type: Interventional
• Enrollment (Actual): 26
• Phase: Phase 1

Contacts and Locations

Study Locations

• Germany
  • Baden-Württemberg
    • Breisgau, Baden-Württemberg, Germany
  • Nordrhein-Westfalen
    • Ruhrgebiet, Nordrhein-Westfalen, Germany

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Males or females with advanced, recurrent or metastatic cancer, refractory to standard therapy;
• Age ≥18 years;
• Signed informed consent form and ability to understand the study procedures.

Exclusion Criteria:

• Concomitant anticancer therapy, including radiation;
• Current or previous (within 30 days of first study dosing) treatment with another investigational drug or participation in another clinical study;
• Chronic daily treatment with aspirin (>325 mg/day) or clopidogrel (>75 mg/day);
• Chronic daily treatment with corticosteroids, with the exception of inhaled steroids;
• Inadequate bone marrow function;
• Inadequate liver function;
• Inadequate renal function;
• Patients not receiving anticoagulant medication who have an International Normalized Ratio (INR) >1.5 or an activated partial thromboplastin time (aPTT) >1.5 x ULN within 7 days prior to first study treatment;
• Patients with lymphomas;
• Evidence of spinal cord compression or brain metastases;
• Other malignancy diagnosed within the previous 5 years;
• Pregnant or lactating females.;
• All patients who do not use a highly effective method of birth control;
• Major surgical procedure (including open biopsy) within 28 days prior to the first study treatment, or anticipation of the need for major surgery during the course of the study treatment;
• Minor surgical procedures, within 24 hours prior to the first study treatment;
• History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding;
• Uncontrolled hypertension or clinically significant (i.e. active) cardiovascular disease;
• History of abdominal fistula, grade 4 bowel obstruction or gastrointestinal perforation, intra-abdominal abscess within 6 months of enrollment;
• Lung carcinoma of squamous cell histology or any histology in close proximity to a major vessel;
• Serious non-healing wound, peptic ulcer or bone fracture;
• Known hypersensitivity to the study medication or any of its excipients;
• Evidence of any other medical conditions that may interfere with the planned treatment, affect patient compliance or place the patient at high risk of treatment-related complications;
• Previous enrollment in this study;
• Known hepatitis B or C or HIV infection;
• Employees of the sponsor or patients who are employees or relatives of the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Angiocal®	Drug: Angiocal® (PRS-050-PEG40); Single dose of Angiocal® i.v. (intravenous) on Day 1 and further applications of Angiocal® i.v. during a repeated dosing period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose limiting toxicity	Dose limiting toxicity is determined by recording and evaluating adverse events / toxicity.	Throughout the course of the study

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetic analysis	AUC_0- τ; AUC_0-tlast; AUC_0-∞; C_max; T_max; t_½; CL; V_z; V_ss; RA_AUC; RA_Cmax; RL; dose normalized values (norm) for AUC_0-τ and C_max will be determined by dividing the original toxicokinetic parameter by the dose level.	Throughout the course of the study
Development of biomarkers in blood over time		Throughout the course of the study
Response of target lesions over time	The objective tumor response for target lesions will be presented over time, employing the categories 'complete response', 'partial response, 'progressive disease´ and 'stable disease' and absolute changes.	Throughout the course of the study
ECOG performance status	ECOG = Eastern Cooperative Oncology Group	Throughout the course of the study
Clinical laboratory measures	Hematology, biochemistry, coagulation parameters, and urinalysis.	Throughout the course of the study
Anti-drug antibodies		Throughout the course of the study
Results of 12-lead Electrocardiogram by time point	Changes from the baseline visit will be presented using shift tables (employing the categories 'normal', 'abnormal, clinically not significant' and 'abnormal, clinically significant') and absolute changes in laboratory values, if appropriate. Changes from the baseline visit in QTc between >30 and <60 ms and >60 ms will be listed and summarized separately.	Throughout the course of the study
Changes of vital signs from the baseline visit	Heart rate, blood pressure and body temperature.	Throughout the course of the study
Physical examination	Any changes in physical examination findings from baseline visit will just be summarized, since the physical examiniations will not result in measurable values.	Throughout the course of the study

Collaborators and Investigators

• Sponsor: Pieris Pharmaceuticals GmbH
• Collaborators: FGK Clinical Research GmbH
• Investigators: Study Director: Laurent Audoly, PhD, Pieris Pharmaceuticals GmbH

Publications and helpful links

General Publications

• Mross K, Richly H, Fischer R, Scharr D, Buchert M, Stern A, Gille H, Audoly LP, Scheulen ME. First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors. PLoS One. 2013 Dec 13;8(12):e83232. doi: 10.1371/journal.pone.0083232. eCollection 2013.

Study record dates

Study Major Dates

• Study Start: May 1, 2010
• Primary Completion (Actual): September 1, 2011
• Study Completion (Actual): September 1, 2011

Study Registration Dates

• First Submitted: May 28, 2010
• First Submitted That Met QC Criteria: June 9, 2010
• First Posted (Estimate): June 10, 2010

Study Record Updates

• Last Update Posted (Estimate): October 19, 2011
• Last Update Submitted That Met QC Criteria: October 18, 2011
• Last Verified: October 1, 2011

More Information

Terms related to this study

• Keywords: Angiocal®; PRS-050-PEG40; Solid tumor; Phase I
• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: Pieris001